GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one ... Wegovy has not yet been registered in South Africa. Rybelsus, the oral tablet form of ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate ...

A new study published in the journal Diabetes & Vascular Disease Research has found that oral semaglutide reduces total energy intake and changes in the food preference in patients with type 2 ...

In 2021, amid the pandemic, she replaced the physical documents with a digital tablet, a practice she has continued ever since. Dressed in an off-white handloom silk saree adorned with fish-themed ...

The Super Bowl logo has become more of a talking point among NFL fans over the last few seasons. Part of the reason for that is a conspiracy theory that the colors of the Super Bowl logo determine ...